Acción CELSION CORPORATION
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Celsion Corporation Nasdaq

Acciones

US15117N3052

Precio de cierre Nasdaq
Otros sitios de cotización
- USD - Gráfico intradía de Celsion Corporation
24/06 Imunon, Inc. Anuncia el bloqueo de la base de datos del estudio de fase 2 OVATION 2 con IMNN-001 en cáncer de ovario avanzado CI
05/06 IMUNON, Inc. anuncia los primeros participantes vacunados en el ensayo clínico de fase 1 IMNN-101 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial
IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial
Imunon : Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting entitled “A Phase II Study Evaluating the effect of IMNN-001 on Second Look Laparoscopy (SLL) when Administered in Combination with Bevacizumab (BEV) and Neoadjuvant Chemother
Imunon : Management Change/Compensation - Form 8-K
Imunon, Inc. Announces CFO Changes, Effective from June 1, 2024
Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
Imunon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024
IMUNON, Inc. Appoints Stacy R. Lindborg as President, Effective May 13, 2024
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción IMNN
  4. Acción
  5. Noticias Celsion Corporation
  6. Otros idiomas